Loteprednol Etabonate Ophthalmic Gel 0.5 %: A Review of Its Use in Post-Operative Inflammation and Pain Following Ocular Surgery
- 302 Downloads
Loteprednol etabonate ophthalmic gel 0.5 % (Lotemax®) is approved in the USA for the treatment of post-operative inflammation and pain in patients who have undergone ocular surgery. The new gel formulation of loteprednol etabonate offers some potential advantages over the previously available ophthalmic suspension and ointment formulations of the drug. Because the gel is non-settling, a uniform dose of loteprednol etabonate is delivered without the need to vigorously shake the product. The pH of the gel formulation is close to that of physiological tears and the concentration of preservative is low. In clinical trials, loteprednol etabonate ophthalmic gel 0.5 % for 14 days was effective, very well tolerated and safe when used for the treatment of post-operative inflammation and pain following cataract surgery. Relative to vehicle, loteprednol etabonate ophthalmic gel 0.5 % effectively reduced postoperative ocular inflammation and ocular pain and had a similar overall tolerability, comfort and safety profile. It is associated with a low risk of inducing clinically significant increases in intraocular pressure. In conclusion, loteprednol etabonate ophthalmic gel 0.5 % is an additional formulation option for the short-term treatment of post-operative inflammation and pain in patients who have undergone ocular surgery. It provides uniform dosing of a topical ophthalmic corticosteroid that has been demonstrated to be effective and well-tolerated in the treatment of ocular inflammation.
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
- 4.Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012. doi: 10.1155/2012/789623.
- 7.American Academy of Ophthalmology Cataract and Anterior Segment Panel. Perferred Practice Pattern Guidelines®: cataract in the adult eye. San Francisco: American Academy of Ophthalmology; 2011.Google Scholar
- 9.Lotemax (loteprednol etabonate ophthalmic suspension 0.5%). US prescribing information. Tampa: Bausch & Lomb Incorporated; 2006.Google Scholar
- 10.Lotemax (loteprednol etabonate ophthalmic ointment 0.5%). US prescribing information. Tampa: Bausch & Lomb Incorporated; 2011.Google Scholar
- 12.A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. The Loteprednol Etabonate Postoperative Inflammation Study Group 2. Ophthalmology. 1998;105(9):1780–6.Google Scholar
- 15.Friedlaender MH, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. The Loteprednol Etabonate Giant Papillary Conjunctivitis Study Group I. Am J Ophthalmol. 1997;123(4):455–64.PubMedGoogle Scholar
- 17.Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444–57.PubMedCrossRefGoogle Scholar
- 18.Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Loteprednol Etabonate US Uveitis Study Group. Am J Ophthalmol. 1999;127(5):537–44.Google Scholar
- 20.Lotemax (loteprednol etabonate ophthalmic gel 0.5%). US prescribing information. Tampa: Bausch & Lomb Incorporated; 2012.Google Scholar
- 27.Alberth M, Wu WM, Winwood D, et al. Lipophilicity, solubility and permeability of loteprednol etabonate: a novel, soft anti-inflammatory steroid. J Biopharm Sci. 1991;2:115–25.Google Scholar
- 34.Wu J-S, Zhong X-W, Zhang X-X, et al. A randomized controlled study on the application of 0.5% loteprednol etabonate eye drops after LASIK surgery. Chin J Exp Ophthalomol. 2012;30(7):641–5.Google Scholar
- 36.Chen M, Gong L, Sun X, et al. A multicenter, randomized, parallel-group, clinical trial comparing the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of Chinese patients with blepharokeratoconjunctivitis. Curr Med Res Opin. 2012;28(3):1–10.CrossRefGoogle Scholar
- 41.Li W-T, Li H, Wei J. Clinical study on the application of 5 g/L loteprednol etabonate ophthalmic suspension after LASIK. Int J Ophthalmol. 2010;10(9):1792–3.Google Scholar
- 42.Gao D-H, Li K-J, Lu H. Clinical observations on the effect of lotemax on changes in intraocular pressure after LASEK. Int J Ophthalmol. 2010;10(9):806–7.Google Scholar
- 43.Glogowski S, Proksch JW. Ocular and systemic pharmacokinetics of loteprednol etabonate gel (0.5%) following topical ocular administration to rabbits [poster no. D1138]. Annual Meeting of the Association for Research in Vision and Ophthalmology; 6–9 May 2012, Fort Lauderdale.Google Scholar
- 44.Aziz R. Pharmacology review(s): New Drug Application Number 202872 (loteprednol etabonate ophthalmic gel, 0.5%). Silver Spring: Center for Drug Evaluation and Research; 2012.Google Scholar
- 45.Comstock TL, Siou-Mermet R, Erb T, et al. Efficacy of loteprednol etabonate gel 0.5% in the treatment of inflammation and pain in post-cataract surgery patients [poster no. 39]. Annual Meeting of the American Academy of Optometry; 24-27 Oct 2012, Phoenix.Google Scholar
- 46.Rajpal RK, Siou-Mermet R, Erb T. Loteprednol etabonate (LE) gel 0.5% in the treatment of ocular inflammation and pain following cataract surgery [poster no. PO021]. Annual Meeting of the American Academy of Opthalmology; 10–13 Nov 2012, Chicago.Google Scholar